Search research articles
Contact Us
Filters
Showing results (171-180 of 193) with videos related to
Page
of 20
Sort By:
The New England Journal of Medicine
|
December 28, 2020
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H Wei, Hartmut Döhner, Christopher Pocock, et al.
Frontiers in Oncology
|
October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
Jesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Haematologica
|
September 24, 2016
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Eline M P Cremers, Theresia M Westers, Canan Alhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood
|
October 11, 2012
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
Gert J Ossenkoppele, Georg Stussi, Johan Maertens, et al.
Hemasphere
|
June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies
Coen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia
|
December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Blood
|
January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Löwenberg, Thomas Pabst, Johan Maertens, et al.
British Journal of Haematology
|
May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Leukemia
|
February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
Rabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 193) with videos related to
Sort By:
Page
of 20
The New England Journal of Medicine
|
December 28, 2020
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H Wei, Hartmut Döhner, Christopher Pocock, et al.
Frontiers in Oncology
|
October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
Jesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Haematologica
|
September 24, 2016
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Eline M P Cremers, Theresia M Westers, Canan Alhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
Stefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood
|
October 11, 2012
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
Gert J Ossenkoppele, Georg Stussi, Johan Maertens, et al.
Hemasphere
|
June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies
Coen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia
|
December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Blood
|
January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Löwenberg, Thomas Pabst, Johan Maertens, et al.
British Journal of Haematology
|
May 26, 2025
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, et al.
Leukemia
|
February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
Rabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Page
of 20